Jing-Jie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing-Jie Wang has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Kaihui Nan
State Key Laboratory of Eye Health, Eye Hospital Wenzhou Medical University Wenzhou Zhejiang China
5 shared publications Xin-Xin Liu
5 shared publicationsSi-Yu Wang
4 shared publicationsXin-Yang Pan
National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China
3 shared publications- Zhimin Zhou
College of Biological and Pharmaceutical Sciences, China Three Gorges University, Yichang 443002, China; Biomedical Barriers Research Center, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
3 shared publications Tian-Zuo Wang
State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou 325027, China
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Materials Today Bio
- Vol. 41
Ocular delivery of repurposed everolimus against dry eye with a tear-triggered in situ hydrogel based on enhanced solubilization and retention
- 27 October 2026
- Published by Elsevier in Materials Today Bio
- Vol. 41
Open AccessOcular delivery of repurposed everolimus against dry eye with a tear-triggered in situ hydrogel based on enhanced solubilization and retention
- Open Access
- 1 July 2025
- Published by Tsinghua University Press in Journal of Otology
- Vol. 20 (3) , 190-197
Intratympanic dexamethasone microcrystal-loaded porous PLGA microspheres containing lipoic acid for combined delivery to the inner ear
Objective To develop a sustained-release codelivery system for intratympanic administration of dexamethasone (DEX) and lipoic acid (LA). Methods DEX microcrystals (MCs) were prepared via precipitation, while LA-loaded porous PLGA microspheres (LPMPs) were fabricated using a double emulsion–solvent evaporation method. DEX MCs were physically perfused into LPMPs via negative pressure to form a combined system (DEX MCs+LPMPs). Physicochemical properties, in vitro drug release, pharmacokinetics, and biocompatibility were evaluated. Guinea pigs were used for intratympanic injections of DEX MCs, LPMPs, or DEX MCs+LPMPs. Results The DEX MCs+LPMPs system enabled simultaneous release of both drugs, with DEX exhibiting superior pharmacokinetics (sustained perilymph concentrations up to 7 days) compared to DEX MCs alone. LA release from LPMPs demonstrated prolonged kinetics without burst release. SEM confirmed DEX MCs were localized within/on LPMPs and adhered to the round window membrane (RWM). Histological analysis revealed normal cochlear morphology and no inflammatory response, confirming biocompatibility. Conclusions This novel codelivery system combining microcrystals and porous microspheres achieves sustained dual-drug release, enhances therapeutic efficacy, and offers a promising strategy for managing hearing loss via intratympanic administration.
- 1 July 2025
- Published by Tsinghua University Press in Journal of Otology
- Vol. 20 (3) , 190-197
Open AccessIntratympanic dexamethasone microcrystal-loaded porous PLGA microspheres containing lipoic acid for combined delivery to the inner ear
Objective To develop a sustained-release codelivery system for intratympanic administration of dexamethasone (DEX) and lipoic acid (LA). Methods DEX microcrystals (MCs) were prepared via precipitation, while LA-loaded porous PLGA microspheres (LPMPs) were fabricated using a double emulsion–solvent evaporation method. DEX MCs were physically perfused into LPMPs via negative pressure to form a combined system (DEX MCs+LPMPs). Physicochemical properties, in vitro drug release, pharmacokinetics, and biocompatibility were evaluated. Guinea pigs were used for intratympanic injections of DEX MCs, LPMPs, or DEX MCs+LPMPs. Results The DEX MCs+LPMPs system enabled simultaneous release of both drugs, with DEX exhibiting superior pharmacokinetics (sustained perilymph concentrations up to 7 days) compared to DEX MCs alone. LA release from LPMPs demonstrated prolonged kinetics without burst release. SEM confirmed DEX MCs were localized within/on LPMPs and adhered to the round window membrane (RWM). Histological analysis revealed normal cochlear morphology and no inflammatory response, confirming biocompatibility. Conclusions This novel codelivery system combining microcrystals and porous microspheres achieves sustained dual-drug release, enhances therapeutic efficacy, and offers a promising strategy for managing hearing loss via intratympanic administration.
- 11 February 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 380, 490-502
Hydrophobic vehicles for hydrophilic drugs: Sustained intravitreal caffeine delivery with oleogels
- 11 February 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 380, 490-502
Hydrophobic vehicles for hydrophilic drugs: Sustained intravitreal caffeine delivery with oleogels
- 1 November 2024
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 25 (11) , 7518-7528
In Situ Gelling Eye Drops of Tacrolimus with Improved Ocular Delivery and Therapeutic Efficacy
In situ gelling eye drops of tacrolimus (FK506 Gel) were developed to address the formulation challenge of tacrolimus for anterior ocular inflammatory diseases. Both in silico and in vitro investigations were conducted to screen a suitable cyclodextrin species to increase the drug solubility. Guanosine was employed as the gelator and combined with inclusion complexes of tacrolimus in the presence of borate anions to obtain FK506 Gel, which gelated when came into contact with cations in tear fluid and led to the formation of a nanofibrous hydrogel. The versatility of our design to improve the solubility and ocular retention of the hydrophobic drug was demonstrated in vivo with coumarin 6 as a model drug. A mouse dry eye model was used to evaluate the therapeutic effects of FK506 Gel, which, in combination with the biocompatibility study, suggested that FK506 Gel served as a superior treatment for anterior ocular inflammatory diseases.
- 1 November 2024
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 25 (11) , 7518-7528
In Situ Gelling Eye Drops of Tacrolimus with Improved Ocular Delivery and Therapeutic Efficacy
In situ gelling eye drops of tacrolimus (FK506 Gel) were developed to address the formulation challenge of tacrolimus for anterior ocular inflammatory diseases. Both in silico and in vitro investigations were conducted to screen a suitable cyclodextrin species to increase the drug solubility. Guanosine was employed as the gelator and combined with inclusion complexes of tacrolimus in the presence of borate anions to obtain FK506 Gel, which gelated when came into contact with cations in tear fluid and led to the formation of a nanofibrous hydrogel. The versatility of our design to improve the solubility and ocular retention of the hydrophobic drug was demonstrated in vivo with coumarin 6 as a model drug. A mouse dry eye model was used to evaluate the therapeutic effects of FK506 Gel, which, in combination with the biocompatibility study, suggested that FK506 Gel served as a superior treatment for anterior ocular inflammatory diseases.
- 7 September 2023
- Published by Japan Society of Applied Physics
Large-area and phase-controlled MoTe2 grown by cold-wall chemical vapor deposition on different substrates
2023 International Conference on Solid State Devices and Materials ,Large-area and phase-controlled MoTe2 grown by cold-wall chemical vapor deposition on different substrates
- 7 September 2023
- Published by Japan Society of Applied Physics
Large-area and phase-controlled MoTe2 grown by cold-wall chemical vapor deposition on different substrates
2023 International Conference on Solid State Devices and Materials ,Large-area and phase-controlled MoTe2 grown by cold-wall chemical vapor deposition on different substrates
- 10 February 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 355, 395-405
Improving ocular bioavailability of hydrophilic drugs through dynamic covalent complexation
- 10 February 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 355, 395-405
Improving ocular bioavailability of hydrophilic drugs through dynamic covalent complexation
- Open Access
- 31 December 2022
- Published by MDPI AG in Bioengineering
- Vol. 10 (1) , 53
Engineering Advanced Drug Delivery Systems for Dry Eye: A Review
Dry eye disease (DED) is a widespread and frequently reported multifactorial ocular disease that not only causes ocular discomfort but also damages the cornea and conjunctiva. At present, topical administration is the most common treatment modality for DED. Due to the existence of multiple biological barriers, instilled drugs generally exhibit short action times and poor penetration on the ocular surface. To resolve these issues, several advanced drug delivery systems have been proposed. This review discusses new dosage forms of drugs for the treatment of DED in terms of their characteristics and advantages. Innovative formulations that are currently available in the market and under clinical investigation are elaborated. Meanwhile, their deficiencies are discussed. It is envisioned that the flourishing of advanced drug delivery systems will lead to improved management of DED in the near future.
- 31 December 2022
- Published by MDPI AG in Bioengineering
- Vol. 10 (1) , 53
Open AccessEngineering Advanced Drug Delivery Systems for Dry Eye: A Review
Dry eye disease (DED) is a widespread and frequently reported multifactorial ocular disease that not only causes ocular discomfort but also damages the cornea and conjunctiva. At present, topical administration is the most common treatment modality for DED. Due to the existence of multiple biological barriers, instilled drugs generally exhibit short action times and poor penetration on the ocular surface. To resolve these issues, several advanced drug delivery systems have been proposed. This review discusses new dosage forms of drugs for the treatment of DED in terms of their characteristics and advantages. Innovative formulations that are currently available in the market and under clinical investigation are elaborated. Meanwhile, their deficiencies are discussed. It is envisioned that the flourishing of advanced drug delivery systems will lead to improved management of DED in the near future.